April 1, 2014

Prasco Labs on Tuesday announced that it has signed a marketing and distribution agreement with Eli Lilly and Co. to market the authorized generic version of Evista (raloxifene hydrochloride tablets), 60 mg strength, in the United States.

April 1, 2014

Teva Pharmaceuticals on Tuesday announced the introduction and availability of Raloxifene hydrochloride tablets, USP.

March 4, 2014

Teva Pharmaceutical Industries announced that it received approval for generic Evista (raloxifene) tablets, 60-mg, in the United States.

August 31, 2010

Eli Lilly's method-of-use patents for its osteoporosis drug were declared valid by a federal court...

May 5, 2010

Watson Pharmaceuticals is challenging the patent covering a drug for postmenopausal women, the generic drug...